文献速递血栓与止血

血管性血友病(p.V1316M)2B型血小板中蛋白激酶C信号功能障碍

Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
PubMed 文献 · Blood Adv · 2018-01-01

研究通过流体动力学基因转移在野生型和Caldaggef1-/-小鼠中表达VWF/p.V1316M,以整合素αIIbβ3活化为读出指标,发现2B型VWD血小板功能障碍影响PKC介导而非CDGI介导的Rap1活化。循环2B型VWD血小板基线PKC底物磷酸化显著增加导致PKC信号缺陷,提示VWF-GPIbα相互作用引起PKC通路预激活和耗竭,并伴GPIbα显著脱落。

要点

  • 2B型VWD血小板功能障碍影响PKC介导而非CDGI介导的Rap1活化。
  • 循环2B型VWD血小板基线PKC底物磷酸化显著增加,提示PKC通路预激活和耗竭。
  • 2B型VWD小鼠表现血小板GPIbα显著脱落,与PKC预激活一致。

核心结论

  • p.V1316M相关2B型VWD血小板功能低下的根本原因是PKC信号改变。

研究设计与样本

  • 在野生型和Caldaggef1-/-小鼠中通过流体动力学基因转移表达VWF/p.V1316M。
  • 以整合素αIIbβ3活化为读出指标,比较PKC介导与CDGI介导的Rap1活化通路。

主要发现

  • 2B型VWD血小板功能障碍影响PKC介导的Rap1活化,不影响CDGI介导的Rap1活化。
  • 刺激后的2B型VWD血小板PKC底物磷酸化降低且颗粒释放受损。
  • 循环2B型VWD血小板基线PKC底物磷酸化显著增加,提示VWF-GPIbα相互作用导致PKC通路预激活和耗竭。
  • 2B型VWD小鼠表现血小板GPIbα显著脱落,与PKC预激活一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

von Willebrand disease (VWD) type 2B is characterized by gain-of-function mutations in von Willebrand factor (VWF), enhancing its binding affinity for the platelet receptor glycoprotein (GP)Ibα. VWD type 2B patients display a bleeding tendency associated with loss of high-molecular-weight VWF multimers and variable thrombocytopenia. We recently demonstrated that a marked defect in agonist-induced activation of the small GTPase, Rap1, and integrin αIIbβ3 in VWD (p.V1316M) type 2B platelets also contributes to the bleeding tendency. Here, we investigated the molecular mechanisms underlying impaired platelet Rap1 signaling in this disease. Two distinct pathways contribute to Rap1 activation in platelets: rapid activation mediated by the calcium-sensing guanine nucleotide exchange factor CalDAG-GEF-I (CDGI) and sustained activation that is dependent on signaling by protein kinase C (PKC) and the adenosine 5'-diphosphate receptor P2Y12. To investigate which Rap1 signaling pathway is affected, we expressed VWF/p.V1316M by hydrodynamic gene transfer in wild-type and Caldaggef1-/- mice. Using αIIbβ3 integrin activation as a read-out, we demonstrate that platelet dysfunction in VWD (p.V1316M) type 2B affects PKC-mediated, but not CDGI-mediated, activation of Rap1. Consistently, we observed decreased PKC substrate phosphorylation and impaired granule release in stimulated VWD type 2B platelets. Interestingly, the defect in PKC signaling was caused by a significant increase in baseline PKC substrate phosphorylation in circulating VWD (p.V1316M) type 2B platelets, suggesting that the VWF-GPIbα interaction leads to preactivation and exhaustion of the PKC pathway. Consistent with PKC preactivation, VWD (p.V1316M) type 2B mice also exhibited marked shedding of platelet GPIbα. In summary, our studies identify altered PKC signaling as the underlying cause of platelet hypofunction in p.V1316M-associated VWD type 2B.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Casari C, Paul DS, Susen S, et al. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. Blood Adv. 2018. PMID: 29925524. doi:10.1182/bloodadvances.2017014290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。